## Gene therapy analytical solutions

Fast, accurate, and scalable methods for gene-therapy-based product manufacturing, analytical testing, and characterization



thermo scientific

# Fast, robust, and confident analysis from characterization through to control

Technologies for manufacturing and the analysis of gene therapy products are evolving. Solutions from Thermo Fisher Scientific are evolving too. Our robust solutions are tailored for the analysis of gene therapy products enabling fast, accurate, and reproducible results accelerating product development path to market.

Introduction

Complexity of AAV gene therapies

Critical quality attributes Empty/full Intact mass capside analysis analysis Capsid protein characterization

n Capsid on sequence and PTM analysis

d Host cell and protein ysis analysis

II New products

End-to-end solutions

## The complexity of AAV gene therapy products

Adeno-associated virus (AAV) based gene therapeutics are far more complex than many traditional biotherapeutics. Besides the full capsid containing the desired gene material, the final product could contain many different types of process and product related impurities.

Viral capsid protein IMPURITIES characterization **Empty capsid Full capsid** The full capsid needs to be carefully characterized to ensure product safety **Partially-filled** and efficacy. capsid Host cell DNAs Incorrect Host cell proteins viral protein ratio CAPSID SHELL Aggregates Impurities need to be accurately measured and controlled to ensure product quality and safety. DNA WITH HEALTHY GENE Empty/full End-to-end Introduction Complexity Critical Intact mass Capsid protein Capsid Host cell New of AAV gene quality capsid analysis characterization sequence and protein products solutions therapies attributes analysis PTM analysis analysis

**Desired AAV** 

vector product

## Critical quality attributes

With the right analytical tools scientists can expedite development of safe, high-quality gene therapy products while reducing time-to-market and costs of manufacturing.



Introduction

Complexity Critical of AAV gene quality therapies attributes Empty/full capsid analysis

full Intact mass d analysis iis Capsid protein characterization

Capsid sequence and PTM analysis Host cell protein analysis End-to-end solutions

New

products

## Native mass spectrometry-based approach to assess the ratio of empty to full AAV-capsids

- Empty capsids, which do not contain the gene therapy of interest, and partial capsids, those containing only a fragment of the gene of interest, are by-products of the AAV production and can impact product safety and efficacy.
- The amount of full, partial, and empty capsids, therefore, needs to be characterized
- A native MS-based approach provides the necessary improvements in sensitivity and selectivity when compared to UV and fluorescence based separation approaches, respectively,





#### MS using the Q Exactive UHMR under native conditions can be used to reliably assess the empty to full ratio of AAV samples

- Full and empty capsids appear in different m/z regions
- Observed mass difference correlates with the mass of the incorporated cargo genome
- · Relative quantification of the amount of full and empty capsids was provided
- Applicable for different serotypes



View complete article\*



Thermo Scientific<sup>™</sup> Q Exactive<sup>™</sup> UHMR (Ultra-High Mass Range) Hybrid Quadrupole-Orbitrap<sup>™</sup> Mass Spectrometer



Empty/full End-to-end Introduction Complexity Critical Intact mass Capsid protein Capsid Host cell New of AAV gene quality capsid analysis characterization sequence and protein products solutions therapies attributes analysis PTM analysis analysis



## Empty/full capsid analysis with anion exchange chromatography using ultraviolet detection

- AEX separation with UV detection provides selectively between empty and full capsids.
- Full capsids are highlighted with the increase in absorption at 260 nm corresponding to its nucleic acid content.
- The fast and robust empty/full capsid separation can be achieved using the Vanguish UHPLC system with ProPac SAX-10 column.
- The biocompatibility of the Vanguish Flex UHPLC system allows for the use of ion exchange and ion-pairing modifying buffer.





View webinar



The grafted anion-exchange surface provides pH-based selectivity control and fast mass transfer for high-efficiency separation



Thermo Scientific<sup>™</sup> Vanguish<sup>™</sup>

Flex UHPLC Systems



Thermo Scientific<sup>™</sup> ProPac<sup>™</sup>



SAX-10 HPLC Columns





Thermo Scientific<sup>™</sup> Chromeleon<sup>™</sup> Chromatography Data System (CDS) Software

Introduction

Complexity Critical of AAV gene quality therapies attributes Empty/full Intact mass capsid analysis analysis

Capsid protein characterization

Capsid sequence and PTM analysis

Host cell protein analysis

End-to-end New products

solutions

Next page



## Empty/full capsid analysis with anion exchange chromatography using fluorescence detection

- AEX separation with fluorescence detection provides increases in sensitivity and accurate ratio information.
- The fast and robust empty/full capsid separation can be achieved using the Vanquish UHPLC system with ProPac SAX-10 column.
- The biocompatibility of the Vanquish Flex UHPLC system allows for the use of ion exchange and ion-pairing modifying buffer.







Thermo Scientific<sup>™</sup> Vanquish<sup>™</sup> Flex UHPLC Systems





Thermo Scientific<sup>™</sup> ProPac<sup>™</sup> SAX-10 HPLC Columns



Thermo Scientific<sup>™</sup> Chromeleon<sup>™</sup> Chromatography Data System (CDS) Software



Complexity Critical of AAV gene quality therapies attributes Empty/full Intact mass capsid analysis analysis

characterization

Capsid sequence and PTM analysis Host cell protein analysis New products

End-to-end solutions





nese American Chromatography Associatio

View webinar

# Understand heterogeneity at a new level with intact mass analysis

AAV capsid composition impacts viral infectivity and gene transduction. To ensure the safety and quality of gene therapies, AAV capsid and their constituent proteins need to be well characterized and monitored.

MS-based Intact mass analysis provides a robust and sensitive approach for capsid characterization. Mass confirmation can be performed with high confidence using the Q Exactive UHMR Hybrid Quadrupole-Orbitrap mass spectrometer. See how a mixture of 3 MDa and 4 MDa virus capsids analyzed under charge reducing conditions span a wide mass range between *m/z* 27,000 and 36,000.





Thermo Scientific™ Q Exactive™ UHMR (Ultra-High Mass Range) Hybrid Quadrupole-Orbitrap™ Mass Spectrometer





Schematic of the injection of ions from the C-trap into the Orbitrap, where they oscillate along the central electrode, inducing an image current, which is recorded and converted into a final m/zspectrum by Fourier transformation



Example native MS spectra





Native MS of virus-like particles: Shown are encapsulin (top), adenovirus dodecahedron (topmiddle), adeno-associated virus serotype 1 (bottom-middle) and cowpea chlorotic mottle virus (bottom)

I	ntroduction	Complexity of AAV gene therapies	Critical quality attributes	Empty/full capsid analysis	Intact mass analysis	Capsid protein characterization	Capsid sequence and PTM analysis	Host cell protein analysis	New products	End-to-e solution
		therapies	attributes	analysis			PTM analysis	analysis		

## Capsid protein characterization

It is important to understand the capsid identity because each AAV serotype has unique capsid proteins that transfer the genetic material to specific cells or organs. Depending on the therapeutic target area, the correct AAV serotype is chosen and identified, then purity monitored. All AAV capsids consist of three proteins (VP1, VP2, and VP3) that share high-sequence homology. Ensuring the identity and purity of these proteins are critical to viral infectivity and viral transfer.

#### Identification of components

Elution order can change the serotype so positive identification by MS is an advantage



Separation of viral capsid proteins (VP1, VP2, VP3) via hydrophilic interaction liquid chromatography (HILIC, left) and reverse phase chromatography (right) with subsequent MS and MS/MS identification

Introduction	Complexity of AAV gene therapies	Critical quality attributes	Empty/full capsid analysis	Intact mass analysis	Capsid protein characterization	Capsid sequence and PTM analysis	Host cell protein analysis	New products	End-to-end solutions

Thermo Scientific<sup>™</sup> HILIC<sup>™</sup>

Thermo Scientific<sup>™</sup> BioPharma

Finder<sup>™</sup> Software

HPLC Columns

# Capsid protein characterization at the peptide level

The correct AAV serotype is selected, then identity and purity are monitored; either on the intact protein level or by peptide mapping. Peptide mapping can be performed using pepsin SMART digest kit, with state-of-the-art consumables and instrumentation, to increase viral protein 1 (VP1) coverage for confidence in your characterization and monitoring of viral capsids.



### Capsid sequence and PTM analysis

## Peptide mapping approaches

Nanoflow for ultimate

- Minimize sample handling
- Trap technology can help with clean up and concentration





### Capsid sequence and PTM analysis

#### Accurate monitoring of post translational modifications



Typsin Pepsin

Enzyme	M235	M604	N57*	N382*	N496*	B569*	N709*
Pepsin	0.80%	0.74%	0%	0.13%	0%	0%	0%
Trypsin	0%	0.43%	6.18%	0%	3.78%	6.64%	7.54%



- Trypsin digestion at pH 8 is known to create process induced deamidation
- Pepsin digestion at pH 2 does not create any process induced modifications
- Where the data is available for trypsin digestion the relative abundance of the PTM is in close agreement between trypsin and pepsin
- Pepsin produces more accurate data for monitoring PTM's in gene therapy capsids
- Less than 1% deamidation observed in peptic digest
- Less than 1% oxidation in all digests

Introduction	Complexity of AAV gene therapies	Critical quality attributes	Empty/full capsid analysis	Intact mass analysis	Capsid protein characterization	Capsid sequence and PTM analysis	Host cell protein analysis	New products	End-to-end solutions

## Host cell protein analysis

Host cell proteins (HCP) can impact quality or safety, or compromise product stability. Peptide analysis by LC-HRAM-MS offers orthogonal solutions for detection and monitoring of HCPs compared to immunological methods with the unbiased discovery of HCP impurities and subsequent quantitation. HRAM MS data combined with Thermo Scientific BioPharma Finder software provides comprehensive HCP qualitative and quantitative analysis.

#### LC-HRAM-MS Host cell protein analysis





Thermo Scientific™ SMART Digest<sup>™</sup> Trypsin Kits



Thermo Scientific<sup>™</sup> Acclaim VANQUISH C18 UHPLC Columns





Thermo Scientific<sup>™</sup> Orbitrap Eclipse<sup>™</sup> Tribrid Mass Spectrometer





Thermo Scientific<sup>™</sup> BioPharma Finder<sup>™</sup> Software



Introduction Complexity of AAV gene therapies

Critical quality attributes Empty/full Intact mass capsid analysis analysis

Capsid protein characterization

Capsid sequence and PTM analysis

Host cell New protein products analysis

End-to-end solutions

## New products

#### Thermo Scientific<sup>™</sup> EASY-Spray<sup>™</sup> PepMap<sup>™</sup> Neo UHPLC Columns

These columns feature easy connectivity, high reproducibility, and excellent separations. Featuring low/zero dead volume for increased sensitivity in sample limited gene therapy applications.



#### Thermo Scientific<sup>™</sup> Vanquish<sup>™</sup> Neo UHPLC System

The Thermo Scientific<sup>™</sup> Vanquish<sup>™</sup> Neo UHPLC system delivers maximum performance 24/7 for nano-, capillary-, and micro-flow LC-MS. The system ensures excellent retention time precision from nano-flow up to 100 µL/min, the unique low-flow split-loop autosampler enhances sample throughput and injection performance. Vanquish Neo UHPLC system is the new standard in low-flow LC.

Introduction

Complexity of AAV gene therapies Critical quality attributes Empty/full Intact mass capsid analysis analysis Capsid protein characterization

Capsid sequence and PTM analysis Host cell protein analysis New E products

End-to-end solutions

## **End-to-end solution provider**

#### Unprecedented potential to treat diseases

Partnering with Thermo Fisher Scientific, with our expertise and unparalleled product portfolio, allows you to accelerate the development of your gene therapy-based products, by utilizing flexible, robust, fast, accurate, and scalable methods for product manufacturing, analytical testing, and characterization.





#### Plasmid construction

- Gene synthesis
- Cloning and assembly
- Large-scale plasmid purification



#### **Vector production**

- · Gene delivery Virusproducing adherent and suspension cells
- · Custom media current Good Manufacturing Practices (cGMP) chemicals and process liquids
- Specialized laboratory equipment



#### **Vector purification**

- Affinity chromatography
- Ion exchange chromatography
- Centrifugation
- Process liquid/buffer preparation services



#### Lot release and characterization

- · Identity, purity, and contamination
- Functional titer
- Empty capsid analysis
- Genomic, proteomic, and cellular analysis tools



#### Formulation, supply chain and logistics

- Aseptic fill and finish
- Cryopreservation
- Cold chain supply logistics
- Clinical trial support
- Global distribution



Introduction

Complexity of AAV gene therapies

Critical quality attributes Empty/full Intact mass capsid analysis analysis

Capsid protein characterization

Capsid sequence and PTM analysis

Host cell protein products analysis

New

End-to-end solutions

## Thermo Fisher

#### thermo scientific



View complete infographic

FDA guidance for industry on characterization requirements for gene therapy products, focus on structure and characteristics of the product, process related impurities, and product related impurities.

Check out this new infographic to discover optimized workflows utilizing leading Thermo Scientific instruments, consumables, and software for AAV product and process characterization.

#### Learn more at thermofisher.com/genetherapyanalysis

For Research Use Only. Not for use in diagnostic procedures. © 2022 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. XX000711-EN 0522M

#### thermo scientific